 | Up a level |
2022
Wolf, J., Heist, R., Kim, T. M., Nishio, M., Dooms, C., Kanthala, R. R., Leo, E., Giorgetti, E., Wang, Y., Mardjuadi, F. I. and Cortot, A. (2022). Efficacy and safety of capmatinib plus spartalizumab in treatment-naive patients with advanced NSCLC harboring MET exon 14 skipping mutation. Ann. Oncol., 33 (7). S. S1007 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2017
Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D., Garon, E., Groen, H., Hochmair, M., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S2399 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D. S. W., Garon, E. B., Groen, H., Hochmair, M. J., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S1578 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380